TrialJournal for immunotherapy of cancer2022

Phase I/II clinical trial of a helper peptide vaccine plus PD-1 blockade in PD-1 antibody-naïve and PD-1 antibody-experienced patients with melanoma (MEL64).

Rick Daniel Vavolizza et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.